Patents by Inventor Sandra CHAMBONNET

Sandra CHAMBONNET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis
    Patent number: 9700540
    Abstract: The invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis, formulations and associations comprising dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: July 11, 2017
    Assignee: SANOFI
    Inventors: Stephane Beilles, Sandra Chambonnet, Jean-Pierre Collaveri
  • Dronedarone for use in Leishmaniasis, Formulations and Associations for Use in Leishmaniasis
    Publication number: 20160151326
    Abstract: The invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis, formulations and associations comprising dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis.
    Type: Application
    Filed: February 1, 2016
    Publication date: June 2, 2016
    Inventors: Stephane BEILLES, Sandra CHAMBONNET, Jean-Pierre COLLAVERI
  • PHARMACEUTICAL COMPOSITION AND DOSAGE FORM COMPRISING DRONEDARONE, AND PREPARATION METHOD THEREOF
    Publication number: 20150196528
    Abstract: The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Inventors: Bernard ABRAMOVICI, Stephane BEILLES, Sandra CHAMBONNET, Jean-Claude GAUTIER
  • Dronedarone for use in Leishmaniasis, Formulations and Associations for Use in Leishmaniasis
    Publication number: 20150150841
    Abstract: The invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis, formulations and associations comprising dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis.
    Type: Application
    Filed: May 22, 2013
    Publication date: June 4, 2015
    Inventors: Stephane Beilles, Sandra Chambonnet, Jean-Pierre Collaveri
  • Pharmaceutical composition and dosage form comprising dronedarone, and preparation method thereof
    Patent number: 9018250
    Abstract: The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: April 28, 2015
    Assignee: Sanofi
    Inventors: Bernard Abramovici, Stephane Beilles, Sandra Chambonnet, Jean-Claude Gautier
  • PHARMACEUTICAL COMPOSITION AND DOSAGE FORM COMPRISING DRONEDARONE, AND PREPARATION METHOD THEREOF
    Publication number: 20130245115
    Abstract: The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent.
    Type: Application
    Filed: May 6, 2013
    Publication date: September 19, 2013
    Applicant: SANOFI
    Inventors: Bernard ABRAMOVICI, Stephane BEILLES, Sandra CHAMBONNET, Jean-Claude GAUTIER